Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Down – Should You Sell?

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) shares gapped down prior to trading on Monday . The stock had previously closed at $21.6950, but opened at $20.37. Hikma Pharmaceuticals shares last traded at $20.37, with a volume of 450 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Citigroup initiated coverage on Hikma Pharmaceuticals in a report on Thursday. They set a “buy” rating on the stock. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Hikma Pharmaceuticals has an average rating of “Hold”.

Hikma Pharmaceuticals Trading Down 6.1%

The company has a quick ratio of 1.06, a current ratio of 1.82 and a debt-to-equity ratio of 0.57. The company’s fifty day simple moving average is $19.76 and its two-hundred day simple moving average is $19.43.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.